Jesus M. Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B. Andersen, Pietro Invernizzi, Guro E. Lind, Trine Folseraas, Stuart J. Forbes, Laura Fouassier, Andreas Geier, Diego F. Calvisi, Joachim C. Mertens, Michael Trauner, Antonio Benedetti, Luca Maroni, Javier Vaquero, Rocio I. R. Macias, Chiara Raggi, Maria J. Perugorria, Eugenio Gaudio, Kirsten M. Boberg, Jose J. G. Marin, Domenico Alvaro

• Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational andCholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.…